Seeking Alpha

Celgene (CELG -6.4%) dips after missing Q1 estimates on all counts despite solid sales growth...

Celgene (CELG -6.4%) dips after missing Q1 estimates on all counts despite solid sales growth and better margins. Net earnings actually jumped 57% Y/Y on strong sales of its flagship blood-cancer treatment Revlimid. Separately, the company says it's entered into a strategic partnership with privately held Epizyme to develop personalized therapies for patients with genetically defined cancers.

Check out Seeking Alpha’s new Earnings Center »

Comments (1)
  • tebert4
    , contributor
    Comments (4) | Send Message
     
    Based on estimated earnings of $4.80 for the current fiscal year, Celgene is trading at a P/E ratio of 15.2, well below its average of 23 during 2011. In spite of missing both revenues and earnings estimates, the stock turned in a stellar quarter and reaffirmed guidance for 2012. With a modest P/E of 18 the stock could be valued at $86.40 by year end, an upside of 20%.This looks like a buying opportunity to me.
    Disclosure: I am long CELG
    26 Apr 2012, 06:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs